GSK plc
GLAXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $31,376,000 | $30,328,000 | $29,324,000 | $34,114,000 |
| % Growth | 3.5% | 3.4% | -14% | – |
| Cost of Goods Sold | $9,048,000 | $8,565,000 | $9,554,000 | $11,603,000 |
| Gross Profit | $22,328,000 | $21,763,000 | $19,770,000 | $22,511,000 |
| % Margin | 71.2% | 71.8% | 67.4% | 66% |
| R&D Expenses | $6,401,000 | $6,223,000 | $5,488,000 | $5,278,000 |
| G&A Expenses | $11,015,000 | $9,385,000 | $8,372,000 | $10,975,000 |
| SG&A Expenses | $11,015,000 | $9,385,000 | $8,372,000 | $10,975,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $891,000 | -$590,000 | $0 | $0 |
| Operating Expenses | $18,307,000 | $15,018,000 | $13,337,000 | $16,310,000 |
| Operating Income | $4,021,000 | $6,745,000 | $6,433,000 | $6,201,000 |
| % Margin | 12.8% | 22.2% | 21.9% | 18.2% |
| Other Income/Exp. Net | -$544,000 | -$681,000 | -$805,000 | -$2,339,000 |
| Pre-Tax Income | $3,477,000 | $6,064,000 | $5,628,000 | $3,862,000 |
| Tax Expense | $526,000 | $756,000 | $707,000 | $346,000 |
| Net Income | $2,575,000 | $4,928,000 | $14,956,000 | $4,385,000 |
| % Margin | 8.2% | 16.2% | 51% | 12.9% |
| EPS | 0.63 | 1.2 | 3.71 | 1.37 |
| % Growth | -47.5% | -67.7% | 170.8% | – |
| EPS Diluted | 0.62 | 1.2 | 3.66 | 1.35 |
| Weighted Avg Shares Out | 4,080,000 | 4,110,092 | 4,026,000 | 3,202,400 |
| Weighted Avg Shares Out Dil | 4,142,000 | 4,111,000 | 4,084,000 | 3,241,600 |
| Supplemental Information | – | – | – | – |
| Interest Income | $60,000 | $48,000 | $76,000 | $28,000 |
| Interest Expense | $640,000 | $775,000 | $879,000 | $784,000 |
| Depreciation & Amortization | $2,551,000 | $2,294,000 | $2,147,000 | $2,122,000 |
| EBITDA | $6,668,000 | $9,083,000 | $8,601,000 | $6,485,000 |
| % Margin | 21.3% | 29.9% | 29.3% | 19% |